RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Synthesis of H-3, H-2(4), and C-14-MK 3814 (preladenant)
Hesk, D., Borges, S., Dumpit, R., Hendershot, S., Koharski, D., McNamara, P., Ren, S., Saluja, S., Truong, V., & Voronin, K. (2017). Synthesis of H-3, H-2(4), and C-14-MK 3814 (preladenant). Journal of Labelled Compounds and Radiopharmaceuticals, 60(4), 194-199. https://doi.org/10.1002/jlcr.3490
MK 3814 is a potent and selective antagonist of the A(2a) receptor. A(2a) receptor antagonists have the potential for the treatment of Parkinson disease. Three distinct isotopically labelled forms of MK 3814 were synthesized. [H-3]MK 3814 was prepared for a preliminary absorption, distribution, metabolism, and excretion data (ADME) evaluation of the compound and [C-14]MK 3814 for more definitive ADME work, including an absorption, metabolism, and excretion study in man. In addition, [H-2(4)]MK 3814 was prepared as an internal standard for a liquid chromatography mass spectrometry bioanalytical method. This paper discusses the synthesis of 3 isotopically labelled forms of MK 3814.
